- Home
- TBBK vs NVCR Comparison
TBBK vs NVCR Comparison
Compare TBBK & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBK
- NVCR
- Stock Information
- Founded
- TBBK 1999
- NVCR 2000
- Country
- TBBK United States
- NVCR Jersey
- Employees
- TBBK N/A
- NVCR N/A
- Industry
- TBBK Major Banks
- NVCR Medical/Dental Instruments
- Sector
- TBBK Finance
- NVCR Health Care
- Exchange
- TBBK Nasdaq
- NVCR Nasdaq
- Market Cap
- TBBK 2.7B
- NVCR 1.8B
- IPO Year
- TBBK 2004
- NVCR 2015
- Fundamental
- Price
- TBBK $50.51
- NVCR $17.49
- Analyst Decision
- TBBK Buy
- NVCR Buy
- Analyst Count
- TBBK 3
- NVCR 5
- Target Price
- TBBK $55.00
- NVCR $26.60
- AVG Volume (30 Days)
- TBBK 564.7K
- NVCR 1.3M
- Earning Date
- TBBK 10-24-2024
- NVCR 10-30-2024
- Dividend Yield
- TBBK N/A
- NVCR N/A
- EPS Growth
- TBBK 16.52
- NVCR N/A
- EPS
- TBBK 3.95
- NVCR N/A
- Revenue
- TBBK $472,015,000.00
- NVCR $549,964,000.00
- Revenue This Year
- TBBK N/A
- NVCR $16.23
- Revenue Next Year
- TBBK $7.05
- NVCR $6.09
- P/E Ratio
- TBBK $12.71
- NVCR N/A
- Revenue Growth
- TBBK 6.71
- NVCR 8.33
- 52 Week Low
- TBBK $29.92
- NVCR $10.87
- 52 Week High
- TBBK $59.26
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- TBBK 44.27
- NVCR 43.24
- Support Level
- TBBK $45.82
- NVCR $15.61
- Resistance Level
- TBBK $59.26
- NVCR $17.31
- Average True Range (ATR)
- TBBK 2.17
- NVCR 1.29
- MACD
- TBBK -0.96
- NVCR 0.05
- Stochastic Oscillator
- TBBK 35.86
- NVCR 11.59
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities-backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, insurance policy cash value-backed lines of credit and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations. The company deposits and non-interest income are generated in the payments business which consists of issuing, acquiring, and automated clearing house accounts.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.